Navigation Links
Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection
Date:9/17/2014

ARMONK, N.Y., Sept. 17 2014 /PRNewswire/ -- IBM (NYSE: IBM) today announced that Caris Life Sciences is using IBM technical computing and storage technology to accelerate the company's molecular profiling services for cancer patients. These services deliver critically important information to help oncologists develop tailored therapeutic plans for each patient's unique cancer, which could lead to better health outcomes and reduced costs to the healthcare system in general.

Today, optimal cancer care requires sophisticated integration of diverse molecular profiling technologies, which analyze the alterations in molecular signaling pathways in a patient's tumor to best match them to potential treatment options or clinical trials by sifting through patient case history treatments, clinical trial data, medical literature, and other emerging evidence. This poses information overload challenges for oncologists who need to make treatment decisions in real time. Today's clinicians need access to sophisticated big data infrastructure and analytical algorithms to optimize clinical decisions.

To help meet this need, Caris is using multiple technologies to develop world-class molecular profiling services that help doctors advance evidence-based, personalized treatment options for cancer patients. It has tested more than 65,000 cancer patients for 70 different molecular markers using multiple technology platforms. These markers are then correlated with 55 FDA-approved cancer therapies and hundreds of clinical trials agents. 

The Caris tumor profiling database is one of the largest datasets in the application of advanced molecular profiling technologies to support clinicians in delivering personalized treatment recommendations – or precision oncology.

"Widespread access to "Big Data" resources is revolutionizing how cancer is diagnosed and treated and requires sophisticated data management and computational capabilities for annotation and analysis," said George Poste, DVM, Ph.D., Vice Chairman, Caris Life Sciences. "Molecular profiling data will soon be measured in the terabyte per patient level. It also has to be stored for years and be organized in a manner that facilitates deep analytic evaluation and ensures data security."

Working with IBM and premier IBM Business Partner Re-Store, Caris has developed a scalable, data-aware and secure infrastructure with IBM systems and servers for complex molecular profiling analysis. This enhanced infrastructure leverages the broadest range of IBM technologies in the life sciences industry. With the support of IBM technical computing and software defined storage technology, Caris can now make recommendations on 55 potentially actionable drug to molecular target associations as a result of being able to profile both genomic and proteomic data– a significant increase over the current 19 therapeutic recommendations using genomic information alone.

By adding IBM Tivoli Storage Manager and code name Elastic Storage to its HPC environment, Caris is able to access and process massive amounts of data at a significantly faster pace.

"Precision cancer diagnosis and treatment requires the ability to process and analyze staggering amounts of genomic and other clinical data with scale and speed, and to accelerate this work, we need to provide clinicians and analysts with technical computing platforms," said Frank N. Lee, Ph.D., Lead Architect, Genomic Medicine, IBM. "IBM technology has helped Caris handle this data volume with greater speed, efficiency and scalability, and at the same time maintain the required security and reliability essential for handling medical and health data."

Learn more about this story on IBM's A Smarter Planet blog: http://ibm.co/1qQwJ9h.
View a video for more details on this story: http://bit.ly/1m8lo4E

About IBM 
Learn more about IBM life sciences at: ibm.com/lifesciences 
Learn more about IBM technical computing systems at: ibm.com/technicalcomputing

About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of precision medicine through quality and innovation.  As the first commercial mover in comprehensive molecular profiling in oncology, Caris Molecular Intelligence™ is an industry vanguard, with 65,000-plus patients profiled and counting. Ordered by nearly 7,000 oncologists in 63 countries, Molecular Intelligence correlates molecular data generated from a patient's tumor with biomarker/drug associations derived from clinical cancer literature. Using a variety of advanced and clinically-relevant technologies, Caris provides oncologists with the most clinically actionable information to help them personalize treatment for cancer patients. This multi-technology approach enables Caris to provide therapeutic guidance for 55 drug associations, compared to the 19 that can be found through use of next-generation sequencing alone. The company is also developing a series of blood tests based on its proprietary Carisome® TOP platform — a revolutionary blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.carislifesciences.com.

Media Contacts:

Christine Douglass
IBM Media Relations
415-545-6737
cgdouglass@us.ibm.com

Chaiti Sen
IBM Media Relations
212-671-9525
csen@us.ibm.com

David Patti
Caris Life Sciences Media Relations
908-421-5971
dpatti@jfkhealth.com

Video - https://www.youtube.com/watch?v=18Pi-twMGuU&feature=youtu.be   
Logo - http://photos.prnewswire.com/prnh/20090416/IBMLOGO


'/>"/>
SOURCE IBM
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Caris Life Sciences Collaborates with GenoSpace to Enhance Data Mining Capabilities to Advance the Molecular Understanding of Cancer
2. Caris Life Sciences Receives Tumor Profiling Industrys First ISO 15189 Medical Laboratory Accreditation
3. The Caristix HL7 Survival Guide: Understand the Complete Interface Lifecycle
4. Dr. Joachim Schorr (PhD) zum Chief Scientific Officer von Caris Life Sciences bestellt
5. Joachim Schorr, PhD, Named Chief Scientific Officer at Caris Life Sciences
6. Denton Vacuum Introduces Vitua, the First Automated TEM Sample Preparation System for the Life Sciences
7. Pressure BioSciences, Inc. to Present at Rodman & Renshaw and SeeThruEquity NY Investment Conferences
8. Burlington Stores, Quiksilver, Hospira, Mylan and Gilead Sciences highlighted as Zacks Bull and Bear of the Day
9. Sangamo BioSciences Announces Target Date For First IND For Sangamos In Vivo ZFN Genome-Editing Platform For Monogenic Diseases
10. Aethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform
11. BioDelivery Sciences to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... ... December 04, 2019 , ... ... announced the Top 17 Master's in Organizational Psychology Degree Programs for 2020. The ... universities in the nation. Each program is evaluated based on curriculum quality, graduation ...
(Date:12/2/2019)... ... December 02, 2019 , ... TopConsumerReviews.com recently awarded ... Remedies aimed at supporting Women’s Fertility and healthy natural ovulation. , Millions of ... some women than for others. Factors like weight, medical conditions, age, and even ...
(Date:11/30/2019)... ... November 29, 2019 , ... Transpara™ 1.6, ... deep learning algorithms to automatically detect potential breast cancer in 2D and 3D ... America (RSNA) meeting, December 1-6, 2019 (ScreenPoint Medical, South Hall #4380). , The ...
Breaking Medicine Technology:
(Date:12/5/2019)... ... December 05, 2019 , ... Intelligent.com, a trusted resource ... RHIT Degree Programs for 2020. The comprehensive research guide is based on an ... evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment. , ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... A November ... as more cities offer them as public transit options. The article highlighted the life-changing ... injury now confined to a bed to a rider fatality after an incident with ...
(Date:12/4/2019)... MINNEAPOLIS (PRWEB) , ... December 04, 2019 , ... ... of the 2019 HREI Insights Awards™, the only national awards dedicated to recognizing ... , The 2019 awards were presented in nine different categories during the ...
(Date:12/4/2019)... , ... December 04, 2019 , ... ... study of AZD4041 for treating tobacco use and dependence. The study will investigate ... nervous system (CNS) penetrant antagonist of orexin-1 (hypocretin-1) receptors that is being developed ...
(Date:12/2/2019)... (PRWEB) , ... December 02, 2019 , ... Interim ... a silver winner of the 2019 Workforce: Optimas Awards . Selected for its ... first and foremost to help combat the nation’s caregiver shortage. By 2025, the U.S. ...
Breaking Medicine News(10 mins):